ASCO 2022 | Targeting AML with multimodal immunotherapeutic approaches
Eunice Wang
• 3 Jun 2022
In this video, Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the targeting of acute myeloid leukemia (AML) through multimodal immunotherapeutic approaches and the potential promise of these approaches. Dr Wang highlights some of these novel immunotherapies, such as anti-CD47 and anti-TIM3 antibodies, and the potential efficacy of these multimodal approaches for the treatment of AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
